Tirzepatide, a novel pharmaceutical agent, has emerged as a groundbreaking advancement in the realm of GLP-1 receptor agonism. Unlike previous GLP-1 receptor agonists, tirzepatide exerts its effects by simultaneously binding both the GLP-1 and GIP receptors. This dual mechanism of action enhances a substantial reduction in hyperglycemia, leading to